OTC Stock Review announces that it has initiated coverage of Assured Pharmacy, Inc. (Pink Sheets:APHY). Assured Pharmacy, a growing chain of specialty pharmacies specializing in servicing patients who live with chronic pain, just reported a 20.8 percent increase in same store sales for June 2010 versus June 2009. In our opinion, this is blockbuster news and further validates APHY's business model, which focuses on rapid growth by providing specialized prescription services while targeting medical professionals who specialize in pain management, like orthopedics, anesthesiologist, neurologist, oncologist, psychiatrist, and physical rehabilitation professionals.
The focus is on treating patients with long-term, acute, chronic pain conditions. APHY provides physicians with a better prescription process by blending a specialized full service model with focused pharmacology in a highly secure, compliance focused environment, while alleviating the burden of the refill and authorization process on the physician's administrative staff. APHY provides patients with a convenient, full service alternative to retail pharmacies in a confidential, caring environment. Revenue is primarily derived from the sale of prescription drugs, opposed to non-prescription drugs, or health and beauty related products, inventoried at traditional pharmacies.
For fiscal 2009 APHY posted $15.5 million in revenues, which is equivalent to its market cap. With APHY posting 20 percent growth in same store sales and closing in on $1.5 million in monthly revenues, in our opinion, the market cap should expand and investors could see a five-fold move on the stock.
The complete report is available at http://www.otcstockreview.com/APHY_Review.pdf.
How gut microbiome and fiber diversity shape chronic disease outcomes